GIP and obesity due to melanocortin 4 receptor deficiency: Subsequently, we assessed whether the infection status had an impact on the metabolic efficacy of best-in-class drugs to treat obesity and diabetes, namely the GLP-1 receptor agonist liraglutide and the GLP-1/GIP co-agonist MAR709.